<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02445222</url>
  </required_header>
  <id_info>
    <org_study_id>CCTL019A2205B</org_study_id>
    <secondary_id>2014-001673-14</secondary_id>
    <nct_id>NCT02445222</nct_id>
  </id_info>
  <brief_title>CD19 CART Long Term Follow Up (LTFU) Study</brief_title>
  <official_title>Long Term Follow-Up of Patients Exposed to Lentiviral-Based CD19 Directed CAR T-Cell Therapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Novartis Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University of Pennsylvania</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Novartis</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Per Health Authorities guidelines for gene therapy medicinal products that utilize
      integrating vectors (e.g. lentiviral vectors), long term safety and efficacy follow up of
      treated patients is required. The purpose of this study is to monitor all patients exposed to
      CD19 directed CAR T-cells (CD19 CART) for 15 years following last CD19 CART (e.g. CTL019)
      infusion to assess the risk of delayed adverse events (AEs), monitor for replication
      competent lentivirus (RCL) and assess long-term efficacy, including vector persistence.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients are enrolled following completion or early discontinuation from a Novartis sponsored
      or supported study of CD19 directed CAR T-Cell treatment and will be followed for 15 years
      post treatment from the last CD19 directed CAR T-Cell treatment. Patients will be monitored
      for safety and efficacy within the primary treatment protocols for the protocol defined
      duration. While every effort will be made to keep patients in follow-up within the respective
      treatment protocol itself, patients can drop off treatment protocols at any time. Patients
      discontinuing from the primary treatment protocols for any reason will be enrolled in this
      long term follow up (LTFU). This will allow collecting data on long term safety and efficacy
      (as applicable) as mandated by the health authorities of all patients treated with CD19 CART
      therapy within the concept of a single protocol.

      Collection of such long term effects of CD19 CART cell therapy will help to further define
      the risk-benefit profile of CD19 CART.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 2, 2015</start_date>
  <completion_date type="Anticipated">September 5, 2036</completion_date>
  <primary_completion_date type="Anticipated">September 5, 2036</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Proportion of pts with listed categories:New malignancies, incidence/exacerbation of pre-existing neurologic disorder,New incidence or exacerbation of a prior rheumatologic or other autoimmune disorder,New incidence of a hematologic disorder</measure>
    <time_frame>at M2 post treatment then M3, M6 and M12, every 6M up to year 5, yearly until year 15.</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Proportion of patients with detectable CD19 CAR transgene levels in peripheral blood by q-PCR at pre- specified post CD19 CART infusion time points</measure>
    <time_frame>at M2 post treatment then M3, M6 and M12, every 6M up to year 5, yearly until year 15 if CD19 CAR transgene is still detectable.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of patients with detectable RCL by VSV-G</measure>
    <time_frame>at M2 post treatment then M3, M6 and M12, every 6M up to year 5, yearly until year 15 if CD19 CAR transgene is still detected</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of patients who relapse or progress among patients who had not relapsed or progressed at study entry/re-entry;Incidence of death</measure>
    <time_frame>at M2 post treatment then M3, M6 and M12, every 6M up to year 5, yearly until year 15.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Absolute B- and T- lymphocyte count</measure>
    <time_frame>at M3, M6, M12 post treatment then every year up to year 5, yearly until year 15 if the CD19 CAR transgene is detected.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Height and weight, Tanner staging, menstrual cycle status</measure>
    <time_frame>at M2 post treatment then M3, M6 and M12, every year up to year 5, yearly until year 15.</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">620</enrollment>
  <condition>Safety LTFU, Pts Receiving CD19 Directed CAR T-Cell Therapy</condition>
  <arm_group>
    <arm_group_label>Previously treated CART CD19 patients</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Patients who previously were exposed to lentiviral-based CT19 directed CART cell therapy</description>
  </arm_group>
  <intervention>
    <intervention_type>Genetic</intervention_type>
    <intervention_name>Previously treated CART CD 19 patients</intervention_name>
    <description>Lentiviral-based CD19 directed CART cell therapy</description>
    <arm_group_label>Previously treated CART CD19 patients</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  All patients who have received anti-CD19 directed CART therapy and completed or
             discontinued early from a Novartis sponsored treatment protocol that utilized
             CD19-directed CART cells or from any CD19 CART trial sponsored by the University of
             Pennsylvania with which Novartis has a contractual agreement to co-develop the CAR
             technology.

          -  Patients who have provided informed consent for the long term follow up study prior to
             their study participation .

        Exclusion Criteria:

          -  There are no specific exclusion criteria for this study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Novartis Pharmaceuticals</last_name>
    <role>Study Director</role>
    <affiliation>Novartis Pharmaceuticals</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Novartis Pharmaceuticals</last_name>
    <phone>1-888-669-6682</phone>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Novartis Pharmaceuticals</last_name>
    <phone>+41613241111</phone>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Mayo Clinic Arizona Mayo Clinic Building</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85054</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Laurie Mihalik</last_name>
      <email>Mihalik.laurie@mayo.edu</email>
    </contact>
    <investigator>
      <last_name>Jose F. Leis</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Childrens Hospital Los Angeles SC CTL019</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90027</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Renna Killen</last_name>
      <phone>323-361-8670</phone>
      <email>rkillen@chla.usc.edu</email>
    </contact>
    <investigator>
      <last_name>Michael Pulsipher</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of California San Francisco SC-4</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94101</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jenai A. Wilmoth</last_name>
      <phone>415-514-6281</phone>
      <email>jenai.wilmoth@ucsf.edu</email>
    </contact>
    <investigator>
      <last_name>Charalambos Andreadis</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Emory University School of Medicine/Winship Cancer Institute</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30322</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Keshawna L. Sherer</last_name>
      <phone>404-778-3708</phone>
      <email>keshawna.sherer@emoryhealthcare.org</email>
    </contact>
    <investigator>
      <last_name>Jonathon Cohen</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Children's Healthcare of Atlanta SC CTL019</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30342</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Katherine Grizzle Garrett</last_name>
      <phone>+1 404 785 2125</phone>
      <email>Katherine.garrett@choa.org</email>
    </contact>
    <investigator>
      <last_name>Muna Qayed</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Chicago Medical Center, Hematology &amp; Oncology</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60637</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Howie Weiner</last_name>
      <phone>773-834-0982</phone>
      <email>hweiner@medicine.bsd.uchicago.edu</email>
    </contact>
    <investigator>
      <last_name>Michael R. Bishop</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Kansas Cancer Center SC</name>
      <address>
        <city>Westwood</city>
        <state>Kansas</state>
        <zip>66205</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Janie Smart</last_name>
      <phone>913-588-6029</phone>
      <email>nsmart@kumc.edu</email>
    </contact>
    <investigator>
      <last_name>Joseph P McGuirk</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Michigan SC - CTL019B2205J</name>
      <address>
        <city>Ann Arbor</city>
        <state>Michigan</state>
        <zip>48109-2800</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nancy McCullough</last_name>
      <email>ntsai@med.umich.edu</email>
    </contact>
    <investigator>
      <last_name>Gregory Yanik</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Michigan Health System SC CTL019</name>
      <address>
        <city>Ann Arbor</city>
        <state>Michigan</state>
        <zip>48109</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Michelle Smith Tucker</last_name>
      <phone>734-936-8538</phone>
      <email>smimiche@umich.edu</email>
    </contact>
    <investigator>
      <last_name>John Magenau</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Minnesota SC-4</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55455</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Maria Gardner</last_name>
      <phone>612-625-1610</phone>
      <email>puzi0004@umn.edu</email>
    </contact>
    <investigator>
      <last_name>Veronika Bachanova</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Children's Mercy Hospital SC</name>
      <address>
        <city>Kansas City</city>
        <state>Missouri</state>
        <zip>64108</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rachel Wilcox</last_name>
      <phone>816-302-6851</phone>
      <email>rwilcox@cmh.edu</email>
    </contact>
    <investigator>
      <last_name>Gary Myers, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Gary D. Myers</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Weill Cornell Medical College</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10065</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tsiporah Shore</last_name>
      <email>tbs2001@med.cornell.edu</email>
    </contact>
    <investigator>
      <last_name>Koen Van Besien</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Duke Unversity Medical Center SC - CTL019B2205J</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27705</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kristine Edwards</last_name>
      <phone>919-668-2967</phone>
      <email>kristine.gurganus@dm.duke.edu</email>
    </contact>
    <contact_backup>
      <last_name>Erin Arbuckle</last_name>
      <phone>919-684-3293</phone>
      <email>erin.arbuckle@duke.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Paul L. Martin</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Cincinnati Children's Hospital Medical Center</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45229-3039</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Melanie Jordan</last_name>
      <phone>513-636-9292</phone>
      <email>melanie.jordan@cchmc.org</email>
    </contact>
    <investigator>
      <last_name>Stella M. Davies</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ohio State Comprehensive Cancer Center/James Cancer Hospital Ohio State Univ.</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43210</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Susan Whitman</last_name>
      <phone>614-688-9494</phone>
      <email>susan.whitman@osumc.edu</email>
    </contact>
    <investigator>
      <last_name>Samantha Jaglowski</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Oregon Health &amp; Science University</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97239</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Beth Zentzis</last_name>
      <phone>503-346-1507</phone>
      <email>zentzis@ohsu.edu</email>
    </contact>
    <investigator>
      <last_name>Brandon Hayes-Lattin</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The Childrens Hospital of Philadelphia CHOP</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Douglas S. Dunbar</last_name>
      <phone>267-425-5837</phone>
      <email>dunbard@mail.med.upenn.edu</email>
    </contact>
    <investigator>
      <last_name>Stephan Grupp</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Pennsylvania</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Michelle Caylor</last_name>
      <phone>215-898-9256</phone>
      <email>mcaylor@mail.med.upenn.edu</email>
    </contact>
    <investigator>
      <last_name>Noelle Frey</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>UTSW/Children's Medical Center</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75235</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alison Patterson</last_name>
      <phone>214-456-2726</phone>
      <email>Alison.patterson@childrens.com</email>
    </contact>
    <investigator>
      <last_name>Theodore Laetsch, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Theodore Laetsch</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>MD Anderson Cancer Center SC</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Souzanne T. Ouzounian</last_name>
      <phone>713-792-2171</phone>
      <email>souzouni@mdanderson.org</email>
    </contact>
    <contact_backup>
      <last_name>Laura Hargraves</last_name>
      <phone>713-792-6594</phone>
      <email>lehargraves@mdanderson.org</email>
    </contact_backup>
    <investigator>
      <last_name>Jason Westin</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Utah Clinical Trials Office</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84108</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Luke Stone</last_name>
      <phone>801-213-3395</phone>
      <email>luke.stone@hsc.utah.edu</email>
    </contact>
    <investigator>
      <last_name>Michael Boyer, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Michael Boyer</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Wisconsin Hospital and Clinics</name>
      <address>
        <city>Madison</city>
        <state>Wisconsin</state>
        <zip>53792</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jenny Weiland</last_name>
      <phone>608-890-8070</phone>
      <email>PedsHemOncResearch@lists.wisc.edu</email>
    </contact>
    <contact_backup>
      <last_name>Celeste Matsushima</last_name>
      <phone>+1 608-890-8069</phone>
      <email>camatsus@pediatrics.wisc.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Christian Capitini</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Melbourne</city>
        <state>Victoria</state>
        <zip>3000</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Parkville</city>
        <state>Victoria</state>
        <zip>3052</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Camperdown</city>
        <zip>NSW</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Vienna</city>
        <zip>A-1090</zip>
        <country>Austria</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Hamilton</city>
        <state>Ontario</state>
        <zip>L8V 1C3</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5G 1X8</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H1T 2M4</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H3T 1C5</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Paris Cedex 10</city>
        <zip>75475</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Paris Cedex 19</city>
        <zip>75935</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Koeln</city>
        <state>Nordrhein-Westfalen</state>
        <zip>50937</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Frankfurt</city>
        <zip>60590</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Wurzburg</city>
        <zip>97080</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Amsterdam</city>
        <zip>1105 AZ</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Esplugues de Llobregat</city>
        <state>Barcelona</state>
        <zip>08950</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>Austria</country>
    <country>Canada</country>
    <country>France</country>
    <country>Germany</country>
    <country>Netherlands</country>
    <country>Spain</country>
    <country>United States</country>
  </location_countries>
  <removed_countries>
    <country>Norway</country>
  </removed_countries>
  <verification_date>January 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 1, 2015</study_first_submitted>
  <study_first_submitted_qc>May 12, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 15, 2015</study_first_posted>
  <last_update_submitted>January 2, 2018</last_update_submitted>
  <last_update_submitted_qc>January 2, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">January 4, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

